The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so magnetite is approved for both type 2 diabetes for reduction of major adverse cardiovascular events but it also has a separate weight loss indication for persons who are obese with BMI above 30 or overweight with a BMI over 27 in the setting of one or more obesity related cardiovascular risk factors who need additional weight management after diet and lifestyle attempts
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
but with with semaglutide something happened that didn't happen before with L glutide which was not only did patients have an improvement in their hemoglobin A1c um but their weight dropped dramatically um and so that led to the obvious question which is should we be considering these drugs for weight loss in people who do not have type 2 diabetes